$11.31 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) This Quarter

Equities research analysts expect that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRSGet Rating) will announce $11.31 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $17.70 million and the lowest estimate coming in at $4.91 million. Pieris Pharmaceuticals posted sales of $15.63 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 27.6%. The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Pieris Pharmaceuticals will report full-year sales of $45.17 million for the current year, with estimates ranging from $19.63 million to $70.70 million. For the next year, analysts anticipate that the business will post sales of $47.01 million, with estimates ranging from $9.33 million to $84.70 million. Zacks’ sales averages are an average based on a survey of research firms that cover Pieris Pharmaceuticals.

Separately, StockNews.com began coverage on shares of Pieris Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.50.

NASDAQ PIRS opened at $3.11 on Tuesday. The firm’s fifty day simple moving average is $3.17 and its two-hundred day simple moving average is $3.66. Pieris Pharmaceuticals has a 12-month low of $1.70 and a 12-month high of $6.15. The firm has a market capitalization of $230.38 million, a P/E ratio of -4.51 and a beta of 1.21.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PIRS. Royal Bank of Canada boosted its stake in shares of Pieris Pharmaceuticals by 226.0% during the second quarter. Royal Bank of Canada now owns 12,975 shares of the biotechnology company’s stock worth $50,000 after buying an additional 8,995 shares during the period. Morgan Stanley grew its position in shares of Pieris Pharmaceuticals by 104.6% in the second quarter. Morgan Stanley now owns 1,675,969 shares of the biotechnology company’s stock valued at $6,419,000 after purchasing an additional 856,793 shares during the last quarter. Truepoint Inc. acquired a new stake in Pieris Pharmaceuticals during the third quarter worth approximately $52,000. Sigma Planning Corp boosted its holdings in shares of Pieris Pharmaceuticals by 1.3% in the 3rd quarter. Sigma Planning Corp now owns 364,484 shares of the biotechnology company’s stock valued at $1,884,000 after purchasing an additional 4,684 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. acquired a new position in shares of Pieris Pharmaceuticals in the 3rd quarter valued at $1,686,000. Institutional investors own 51.91% of the company’s stock.

Pieris Pharmaceuticals Company Profile (Get Rating)

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Featured Stories

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.